Orchid Health, a company that does whole-genome DNA sequencing of IVF embryos.
It commercially screens embryos for disease and health risks — pitched as disease-risk screening, not an openly advertised intelligence boost.
It sequences the entire genome of each IVF embryo at roughly $2,500 per embryo to flag disease risks. Unlike a rival (Heliospect) it doesn't market IQ, but it has been accused by the Psychiatric Genomics Consortium of using restricted data.
It marks the arrival of picking embryos by their DNA as a paid service — raising the question of where health screening ends and designer selection begins.